S&P 500   4,274.04 (-0.72%)
DOW   33,980.32 (-0.50%)
QQQ   328.48 (-1.14%)
AAPL   174.59 (+0.90%)
MSFT   291.20 (-0.52%)
META   174.65 (-2.69%)
GOOGL   119.46 (-1.84%)
AMZN   142.04 (-1.89%)
TSLA   911.74 (-0.86%)
NVDA   183.26 (-2.93%)
NIO   20.08 (-3.97%)
BABA   89.78 (-3.10%)
AMD   98.22 (-1.98%)
MU   61.64 (-3.48%)
T   18.41 (-0.86%)
CGC   4.07 (+7.67%)
F   16.04 (-2.37%)
GE   79.89 (-1.46%)
DIS   122.79 (-1.74%)
AMC   21.10 (-14.95%)
PYPL   99.39 (-2.64%)
PFE   49.27 (-1.18%)
NFLX   241.03 (-1.90%)
S&P 500   4,274.04 (-0.72%)
DOW   33,980.32 (-0.50%)
QQQ   328.48 (-1.14%)
AAPL   174.59 (+0.90%)
MSFT   291.20 (-0.52%)
META   174.65 (-2.69%)
GOOGL   119.46 (-1.84%)
AMZN   142.04 (-1.89%)
TSLA   911.74 (-0.86%)
NVDA   183.26 (-2.93%)
NIO   20.08 (-3.97%)
BABA   89.78 (-3.10%)
AMD   98.22 (-1.98%)
MU   61.64 (-3.48%)
T   18.41 (-0.86%)
CGC   4.07 (+7.67%)
F   16.04 (-2.37%)
GE   79.89 (-1.46%)
DIS   122.79 (-1.74%)
AMC   21.10 (-14.95%)
PYPL   99.39 (-2.64%)
PFE   49.27 (-1.18%)
NFLX   241.03 (-1.90%)
S&P 500   4,274.04 (-0.72%)
DOW   33,980.32 (-0.50%)
QQQ   328.48 (-1.14%)
AAPL   174.59 (+0.90%)
MSFT   291.20 (-0.52%)
META   174.65 (-2.69%)
GOOGL   119.46 (-1.84%)
AMZN   142.04 (-1.89%)
TSLA   911.74 (-0.86%)
NVDA   183.26 (-2.93%)
NIO   20.08 (-3.97%)
BABA   89.78 (-3.10%)
AMD   98.22 (-1.98%)
MU   61.64 (-3.48%)
T   18.41 (-0.86%)
CGC   4.07 (+7.67%)
F   16.04 (-2.37%)
GE   79.89 (-1.46%)
DIS   122.79 (-1.74%)
AMC   21.10 (-14.95%)
PYPL   99.39 (-2.64%)
PFE   49.27 (-1.18%)
NFLX   241.03 (-1.90%)
S&P 500   4,274.04 (-0.72%)
DOW   33,980.32 (-0.50%)
QQQ   328.48 (-1.14%)
AAPL   174.59 (+0.90%)
MSFT   291.20 (-0.52%)
META   174.65 (-2.69%)
GOOGL   119.46 (-1.84%)
AMZN   142.04 (-1.89%)
TSLA   911.74 (-0.86%)
NVDA   183.26 (-2.93%)
NIO   20.08 (-3.97%)
BABA   89.78 (-3.10%)
AMD   98.22 (-1.98%)
MU   61.64 (-3.48%)
T   18.41 (-0.86%)
CGC   4.07 (+7.67%)
F   16.04 (-2.37%)
GE   79.89 (-1.46%)
DIS   122.79 (-1.74%)
AMC   21.10 (-14.95%)
PYPL   99.39 (-2.64%)
PFE   49.27 (-1.18%)
NFLX   241.03 (-1.90%)
NASDAQ:ILMN

Illumina - ILMN Stock Forecast, Price & News

$213.11
-6.72 (-3.06%)
(As of 08/17/2022 03:59 PM ET)
Add
Compare
Today's Range
$210.70
$218.58
50-Day Range
$177.23
$233.53
52-Week Range
$173.45
$525.00
Volume
54,843 shs
Average Volume
1.52 million shs
Market Capitalization
$33.48 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$284.45

Illumina MarketRank™ Forecast

Analyst Rating
Hold
2.30 Rating Score
Upside/​Downside
20.3% Upside
$259.21 Price Target
Short Interest
Healthy
1.90% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
-0.17mentions of Illumina in the last 14 days
Based on 66 Articles This Week
Insider Trading
Selling Shares
$161,512 Sold Last Quarter
Proj. Earnings Growth
64.03%
From $2.78 to $4.56 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.70 out of 5 stars

Medical Sector

91st out of 1,122 stocks

Analytical Instruments Industry

7th out of 31 stocks

ILMN stock logo

About Illumina (NASDAQ:ILMN) Stock

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.

Analysts Set New Price Targets

ILMN has been the topic of several research analyst reports. Stifel Nicolaus lowered their price objective on Illumina from $480.00 to $300.00 and set a "buy" rating on the stock in a research report on Friday, August 12th. Morgan Stanley dropped their target price on Illumina from $350.00 to $240.00 and set an "equal weight" rating for the company in a research report on Friday, August 12th. Cowen decreased their price target on shares of Illumina from $506.00 to $492.00 in a research note on Friday, May 6th. UBS Group dropped their price objective on shares of Illumina from $350.00 to $245.00 and set a "neutral" rating on the stock in a research note on Wednesday. Finally, Barclays decreased their price target on Illumina to $130.00 in a research note on Monday. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, Illumina currently has an average rating of "Hold" and an average price target of $259.21.

Illumina Trading Down 3.0 %

NASDAQ:ILMN opened at $219.83 on Wednesday. The company's fifty day simple moving average is $201.67 and its 200-day simple moving average is $272.28. The company has a current ratio of 1.00, a quick ratio of 0.82 and a debt-to-equity ratio of 0.05. The stock has a market cap of $34.54 billion, a P/E ratio of -3,663.22, a PEG ratio of 2.62 and a beta of 1.15. Illumina has a 52 week low of $173.45 and a 52 week high of $525.00.

Illumina (NASDAQ:ILMN - Get Rating) last released its quarterly earnings data on Thursday, August 11th. The life sciences company reported $0.57 EPS for the quarter, missing analysts' consensus estimates of $0.63 by ($0.06). The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.22 billion. Illumina had a positive return on equity of 5.61% and a negative net margin of 0.43%. The business's revenue for the quarter was up 3.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.87 EPS. Equities research analysts predict that Illumina will post 2.78 EPS for the current fiscal year.

Insider Transactions at Illumina

In related news, SVP Alexander Aravanis sold 539 shares of the firm's stock in a transaction that occurred on Thursday, July 7th. The shares were sold at an average price of $200.00, for a total transaction of $107,800.00. Following the completion of the sale, the senior vice president now directly owns 3,346 shares in the company, valued at $669,200. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, SVP Alexander Aravanis sold 539 shares of the business's stock in a transaction on Thursday, July 7th. The shares were sold at an average price of $200.00, for a total transaction of $107,800.00. Following the transaction, the senior vice president now directly owns 3,346 shares in the company, valued at approximately $669,200. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Susan H. Tousi sold 250 shares of the stock in a transaction on Friday, June 10th. The stock was sold at an average price of $214.85, for a total transaction of $53,712.50. Following the transaction, the senior vice president now owns 41,833 shares in the company, valued at approximately $8,987,820.05. The disclosure for this sale can be found here. Company insiders own 0.13% of the company's stock.

Receive ILMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.

ILMN Stock News Headlines

Agilent Technologies Proves Its Worth VS Illumina  (ILMN)
Agilent Technologies proved its worth in FQ3 and was able to raise guidance as well, sending its shares higher as it continues to outperform Illumina.
How High Can Copper Go?
To power the green revolution, copper demand continues to skyrocket with no end in sight. Prices hit a 10-year high; as copper jumped 79% in the past year. Some analysts are calling for copper to rise another 50-100%! We may be at the beginning of a copper bull run the likes we've never seen before. Just how high can copper go?
Illumina (NASDAQ:ILMN) Price Target Cut to $130.00
Illumina Whale Trades Spotted - Benzinga
How High Can Copper Go?
To power the green revolution, copper demand continues to skyrocket with no end in sight. Prices hit a 10-year high; as copper jumped 79% in the past year. Some analysts are calling for copper to rise another 50-100%! We may be at the beginning of a copper bull run the likes we've never seen before. Just how high can copper go?
Illumina (NASDAQ:ILMN) PT Lowered to $220.00 at SVB Leerink
Illumina (NASDAQ:ILMN) Given New $327.00 Price Target at Cowen
Company News for Aug 15, 2022
Illumina (NASDAQ:ILMN) PT Lowered to $300.00
Illumina (NASDAQ:ILMN) Price Target Cut to $240.00
Illumina (NASDAQ:ILMN) Price Target Cut to $200.00
Illumina Whale Trades For August 12 - Benzinga
See More Headlines
Receive ILMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.

ILMN Company Calendar

Last Earnings
8/11/2022
Today
8/17/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:ILMN
CUSIP
45232710
Employees
9,150
Year Founded
1998

Price Target and Rating

Average Stock Price Forecast
$259.21
High Stock Price Forecast
$492.00
Low Stock Price Forecast
$130.00
Forecasted Upside/Downside
+33.5%
Consensus Rating
Hold
Rating Score (0-4)
2.30
Research Coverage
11 Analysts

Profitability

Net Income
$762 million
Pretax Margin
0.23%

Debt

Sales & Book Value

Annual Sales
$4.53 billion
Cash Flow
$7.07 per share
Book Value
$66.48 per share

Miscellaneous

Free Float
156,896,000
Market Cap
$33.48 billion
Optionable
Optionable
Beta
1.15

Social Links















ILMN Stock - Frequently Asked Questions

Should I buy or sell Illumina stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View ILMN analyst ratings
or view top-rated stocks.

What is Illumina's stock price forecast for 2022?

10 brokerages have issued twelve-month target prices for Illumina's stock. Their ILMN share price forecasts range from $130.00 to $492.00. On average, they predict the company's stock price to reach $260.31 in the next year. This suggests a possible upside of 18.4% from the stock's current price.
View analysts price targets for ILMN
or view top-rated stocks among Wall Street analysts.

How have ILMN shares performed in 2022?

Illumina's stock was trading at $380.44 on January 1st, 2022. Since then, ILMN shares have decreased by 42.2% and is now trading at $219.83.
View the best growth stocks for 2022 here
.

When is Illumina's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our ILMN earnings forecast
.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) released its earnings results on Thursday, August, 11th. The life sciences company reported $0.57 earnings per share for the quarter, missing analysts' consensus estimates of $0.63 by $0.06. The life sciences company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.22 billion. Illumina had a negative net margin of 0.43% and a positive trailing twelve-month return on equity of 5.61%. The company's revenue for the quarter was up 3.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.87 EPS.
Read the conference call transcript
.

What guidance has Illumina issued on next quarter's earnings?

Illumina updated its FY22 earnings guidance on Thursday, August, 11th. The company provided earnings per share (EPS) guidance of $2.75-$2.90 for the period, compared to the consensus earnings per share estimate of $4.13. The company issued revenue guidance of $4.67-$4.72 billion, compared to the consensus revenue estimate of $5.21 billion.

What is Francis deSouza's approval rating as Illumina's CEO?

496 employees have rated Illumina Chief Executive Officer Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among the company's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), PayPal (PYPL), Salesforce (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

What is Illumina's stock symbol?

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Who are Illumina's major shareholders?

Illumina's stock is owned by many different retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (12.69%), Loomis Sayles & Co. L P (2.38%), Northern Trust Corp (1.05%), Veritas Asset Management LLP (1.00%), GUARDCAP ASSET MANAGEMENT Ltd (0.88%) and UBS Asset Management Americas Inc. (0.55%). Insiders that own company stock include Aimee L Hoyt, Alexander Aravanis, Charles Dadswell, Frances Arnold, Francis A Desouza, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Sam Samad, Susan H Tousi and Susan H Tousi.
View institutional ownership trends
.

How do I buy shares of Illumina?

Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Illumina's stock price today?

One share of ILMN stock can currently be purchased for approximately $219.83.

How much money does Illumina make?

Illumina (NASDAQ:ILMN) has a market capitalization of $34.54 billion and generates $4.53 billion in revenue each year. The life sciences company earns $762 million in net income (profit) each year or ($0.06) on an earnings per share basis.

How many employees does Illumina have?

The company employs 9,150 workers across the globe.

Does Illumina have any subsidiaries?
The following companies are subsidiares of Illumina: Advanced Liquid Logic Inc., Affomix Corporation, BlueBee, BlueBee Belgium BVBA, BlueBee Holding BV, BlueGnome Ltd, BlueGnome Ltd., Conexio Genomics, Conexio Genomics Pty Ltd., Edico Genome, Emedgene Inc., Emedgene Technologies Ltd, Enancio, Enancio SAS, Epicentre Biotechnologies, GRAIL LLC, GenoLogics, Grail, Helixis, Illumina (China) Scientific Co Ltd, Illumina AB, Illumina Australia Pty. Ltd., Illumina Belgium BVBA, Illumina Brasil Produtos de Biotecnologia Ltda., Illumina Cambridge Ltd., Illumina Canada ULC, Illumina Denmark ApS, Illumina Finland Oy, Illumina France Sarl, Illumina GmbH, Illumina Hong Kong Limited, Illumina India Biotechnology Private Limited, Illumina Ireland Commercial Limited, Illumina Italy S.r.l., Illumina K.K. Japan, Illumina Korea Ltd., Illumina Netherlands B.V., Illumina New Zealand Limited, Illumina Norway AS, Illumina Productos de Espana S.L.U., Illumina Rus LLC, Illumina Shanghai (Trading) Co Ltd Beijing Branch, Illumina Shanghai (Trading) Co. Ltd., Illumina Singapore Pte. Ltd., Illumina Software Inc., Illumina Switzerland GmbH, Illumina US Manufacturing Operations Inc., Liquid Logic, Moleculo, NextBio, Solexa, Verinata Health, Verinata Health Inc., and thromboDx BV.
Read More
When was Illumina founded?

Illumina was founded in 1998.

How can I contact Illumina?

Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The official website for the company is www.illumina.com. The life sciences company can be reached via phone at (858) 202-4500, via email at ir@illumina.com, or via fax at 858-202-4766.

This page (NASDAQ:ILMN) was last updated on 8/17/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.